harmacare
The Authors Respond
Expensive Drugs for Rare Diseases in Canada: Time for Action Everywhere and by Everyone
Sandra Sirrs, Helen Anderson, Bashir Jiwani, Eric Lun, Bob Nakagawa, Dean Regier, Shirin Rizzardo an...
Research Paper
Patent “Evergreening” of Medicine–Device Combination Products: A Global Perspective
Reed F. Beall, Tali Glazer, Haris Ahmad, Mikayla Buell, Slane Hahn, Adam R. Houston, Aaron S. Kessel...
Research Paper
Exploring Privatization in Canadian Primary Care: An Environmental Scan of Primary Care Clinics Accepting Private Payment
Aidan Bodner, Sarah Spencer, M. Ruth Lavergne and Lindsay Hedden
Innovation in Health Services
Cost Impact of a Pharmacist-Driven Medication Reconciliation Program during Transitions to Long-Term Care and Retirement Homes
Denis O’Donnell, Carla Beaton, June Liang, Kisalaya Basu, Michael Hum, Amanda Propp, Liz Yanni, Y...
Discussion and Debate
Commentary: Expedited Regulatory Review of Low-Value Drugs
Jonathan J. Darrow and Reed F. Beall
Research Paper
Developing a Canadian Real-World Evidence Action Plan across the Drug Life Cycle
Mina Tadrous, Tarry Ahuja, Basanti Ghosh and Rhonda Kropp
Research Paper
Ten Years of Inaction on Antimicrobial Resistance: An Environmental Scan of Policies in Canada from 2008 to 2018
Susan Rogers Van Katwyk, Jeremy M. Grimshaw and Steven J. Hoffman
CIHI Survey
Prescribed Drug Spending in Canada, 2019: A Focus on Public Drug Program
Kathy Lee, Trupti Jani, Roger Cheng and Jordan Hunt
Patient Safety
Adverse Drug Reactions in Canada (2009–2018): Insights from the Canada Vigilance Database
Tuhin S. Maity and Christopher J. Longo